Q2 2024 Urogen Pharma Ltd Earnings Call Transcript
Key Points
- UroGen Pharma Ltd (URGN) reported positive 12-month duration of response data from the ENVISION study for UGN-102, showing an unprecedented 82.3% duration of response at 12 months.
- The company is preparing for the NDA submission for UGN-102, with an expected approval decision as early as the first quarter of 2025, potentially transforming the treatment paradigm for bladder cancer.
- UGN-102 has a significant market opportunity estimated at over $5 billion, with the potential to be the first FDA-approved medicine for low-grade intermediate risk non-muscle invasive bladder cancer.
- JELMYTO generated net product revenue of $21.8 million in the second quarter, representing a 16% sequential growth from the first quarter.
- UroGen Pharma Ltd (URGN) successfully raised approximately $116.2 million through a public offering, strengthening its balance sheet and supporting the launch of UGN-102.
- JELMYTO's revenue growth was below expectations due to growing 340b and wastage provision headwinds, as well as a contraction in path conversions from the prior year.
- The company reported a net loss of $33.4 million for the second quarter, compared to $24.1 million in the same period in 2023.
- Research and development expenses increased to $15.4 million in the second quarter, primarily due to higher costs related to manufacturing of UGN-102.
- Selling and marketing expenses rose to $18.9 million, driven by UGN-102 brand marketing costs and increased commercial operation expenses.
- The company faces challenges in patient identification and conversion for JELMYTO, impacting revenue realization despite increased patient enrollment forms.
Good day and thank you for standing by, and welcome to the 2024 second-quarter UroGen Pharma Earnings Call. (Operator instructions) Please be advised that today's conference is being recorded on.
I'd like to hand the conference over to your first speaker today, Mr. Perrone, Head of Investor Relations. Please go ahead.
Thank you, operator. Good morning, everyone, and welcome to UroGen Pharma's second-quarter 2024 financial results and business update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended June 30, 2024. The press release can be accessed on the Investors portion of our website at investors.urogen.com.
Joining me today are Liz Barrett, President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; David Lin, Chief Commercial Officer; and Don Kim, Chief Financial Officer.
During today's call, we will be making certain forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
